【摘要】 氢溴酸达非那新由诺华公司研发,2005年1月首次在德国上市。达非那新为一种选择性毒蕈碱受体阻断剂,对胆碱M3受体具有较强的选择性.达非那新是首个上市的选择性M3受体阻滞剂,对M3受体的选择性比其他受体亚型高59倍,控制膀胱收缩的同时,不产生认知功能损害及心血管的不良反应,临床耐受性好,具有广阔的市场前景。本文对达非那新的研究进展和合成方法进行了综述,希望能找出一条更优化的合成路线。更多还原

【Abstract】 is developed by Novartis,the first time in Germany in January 2005.Darifenacin is a selective muscarinic receptor blockers,cholinergic M3 receptor has a strong selective.Darifenacin is the first listing of selective M3 receptor blockers,M3 receptor selectivity is 59 times higher than the other receptor subtypes.It control bladder contraction,and it does not produce cognitive impairment and cardiovascular adverse reactions at the same time.It clinical tolerability,and has broad market prospects.This paper reviewes darifenacin progress and synthesis methods,and hopes to fine a more optimizes synthenic route.更多还原